Project MR#1 Update:
08 September 2009
Dr Ricky Johnstone and his colleagues have progressed their pre-clinical studies aimed to develop new therapeutic strategies for the treatment of multiple myeloma.
Using the most sophisticated experimental mouse model of human multiple myeloma available, Dr. Johnstone has successfully demonstrated that a class of drugs known as histone deacetylase inhibitors (HDACi) can significantly decrease tumor burden in this model and studies have been initiated using HDACi in combination with other anti-cancer agents in order to increase the therapeutic efficacy.
These experiments serve as important pre-clinical studies to identify novel therapeutic regimens for the treatment of human multiple myeloma that has increased therapeutic benefit and minimises toxic side effects.
Using positron emission tomography (PET) to track the regression of HDACi- treated mice with Eµmyc lymphoma.
FDG uptake is rapidly reduced in Vorinostat-responsive tumours. Fluorodeoxyglucose-based positron emission tomography (FDG-PET) uptake was measured in C57BL/6 mice previously injected with Eµ-myc lymphomas
(Left) before, (Centre) 4 hours and (Right) 24 hours after one 200 mg/kg dose of Vorinostat.
To read more about the MR#1 project, click here.